☆ 4.2 Article

Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab

EUROPEAN NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data

Simona Guerzoni et al.

Summary: Patients affected by CM and MOH showed a significant worsening of headaches in terms of increased migraine days per month, higher painkiller consumption, and greater migraine-related disability after discontinuing erenumab. Factors such as high body mass index and presence of aura were positively correlated with the relapse of CM and MOH.

NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Clinical Neurology

Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study

Pablo Irimia et al.

Summary: A study conducted in Spain found a high discontinuation rate for migraine prophylaxis, which was associated with increased healthcare resource use and costs for non-persistent patients. Therefore, maintaining treatment adherence not only leads to clinical benefits but also reduces healthcare resource utilization and costs.

JOURNAL OF HEADACHE AND PAIN (2022)

Add to Collection

Article Clinical Neurology

Erenumab Discontinuation After 12-Month Treatment A Multicentric, Observational Real-Life Study

Francesca Schiano di Cola et al.

Summary: After discontinuation of erenumab treatment, there was a rapid worsening of migraine symptoms, despite clinical improvement observed during retreatment. It may be necessary to reconsider the timing of treatment discontinuation due to the high frequency and degree of worsening seen during discontinuation.

NEUROLOGY-CLINICAL PRACTICE (2021)

Add to Collection

Article Clinical Neurology

Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial

Messoud Ashina et al.

Summary: This study found that treatment with erenumab led to a reduction in migraine frequency, improvement in health-related quality of life, and these effects were maintained for at least 5 years. No new safety signals were observed during the 5 years of exposure.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study

Piero Barbanti et al.

Summary: Erenumab 70 mg is effective, safe, and well tolerated in real life. Easily obtainable clinical features might be of help in predicting patient's responsiveness.

HEADACHE (2021)

Add to Collection

Article Clinical Neurology

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

Fabrizio Vernieri et al.

Summary: The study aimed to evaluate the effect of discontinuing mAbs anti-CGRP on migraine patients. Results showed that migraine frequency and disability gradually increased after stopping the treatment, but most patients did not relapse to medication overuse or chronic migraine.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Article Clinical Neurology

Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies

Richard B. Lipton et al.

Summary: The study confirmed that erenumab significantly reduces monthly migraine pain in patients with episodic and chronic migraine, and also significantly reduces monthly average pain intensity in episodic migraine patients.

CEPHALALGIA (2021)

Add to Collection

Article Clinical Neurology

Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency

Ryotaro Ishii et al.

Summary: The study findings suggest that using a 15 headache day/month threshold to distinguish episodic and chronic migraine does not fully capture the burden of illness or reflect the treatment needs of patients, which has important implications for future refinements in migraine classification.

HEADACHE (2021)

Add to Collection

Article Clinical Neurology

Proposed new diagnostic criteria for chronic migraine

Mona Ameri Chalmer et al.

CEPHALALGIA (2020)

Add to Collection

Editorial Material Clinical Neurology

International Classification of Headache Disorders-ICHD-4 alpha

Peter J. Goadsby et al.

CEPHALALGIA (2020)

Add to Collection

Article Clinical Neurology

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

Raffaele Ornello et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Article Clinical Neurology

Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study

Dawn C. Buse et al.

HEADACHE (2020)

Add to Collection

Article Clinical Neurology

Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study

Francesca Schiano di Cola et al.

NEUROLOGICAL SCIENCES (2020)

Add to Collection

Review Clinical Neurology

Migraine Progression: A Systematic Review

Dawn C. Buse et al.

HEADACHE (2019)

Add to Collection

Article Clinical Neurology

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability

Richard B. Lipton et al.

HEADACHE (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.